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Abstract Human tissue prokallikrein, a zymogen of the
kallikrein-kinin system, circulates in plasma bound to neutro-
phils. Because plasma kininogens contribute to the assembly of
kinin-generating components on blood cells, these proteins were
assessed for their ability to complex the kallikrein precursor.
Using ligand blot and direct binding assays, biotinylated
prokallikrein was found to bind only to high-molecular-weight
kininogen and not to the low-molecular-weight form. The
interaction was specific, reversible, and saturable yielding an
estimated dissociation constant KD = 690 nM and a 1:1
stoichiometry. Specific kininogen binding of tissue prokallikrein
also occurred at physiological plasma protein concentrations.
These results provide the first evidence for a novel function of
high-molecular-weight kininogen as a binding protein for tissue
prokallikrein that could serve to localize the kallikrein precursor
on the neutrophil surface.
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1. Introduction
Human tissue prokallikrein, the zymogen of the serine pro-
teinase tissue kallikrein (EC 3.4.21.35), has been implicated in
acute in£ammatory reactions, and all components of the pro-
kallikrein-driven cascade system, i.e. tissue kallikrein, kinino-
gens, and kinin peptides have been found in in£ammatory
e¡usions [1]. Abnormal levels of these factors in synovial £uid
from in£amed joints and in bronchoalveolar lavage £uid from
lower airways are associated with the pathogenesis of arthritis
and asthma [2,3]. The abundance of tissue kallikrein is regu-
lated at the levels of transcription [4] and posttranslation, the
latter most likely through site-directed activation of prokalli-
krein [5]. This 245-amino-acid zymogen precursor is converted
into the active enzyme by limited proteolysis of a single pep-
tide bond at position 7 to release mature tissue kallikrein
which, in turn, can liberate the kinin decapeptide kallidin
(lysyl-bradykinin) from high- or low-molecular-weight kinino-
gen (HK, LK) [6]. Kinins are locally active hormones that, by
binding to speci¢c receptors at target cells, regulate vascular
permeability, induce neutrophil chemotaxis, and mediate in-
£ammatory cascades [7]. Gene expression of the kinin-forming
kallikrein precursor occurs in multiple tissues and exocrine
glands of the human body [7], but in the circulation, biosyn-
thesis of prokallikrein mRNA has been demonstrated in hu-
man neutrophils only [8]. Recently, direct evidence for the
presence of immunoreactive tissue prokallikrein in cytoplas-
mic granules of circulating neutrophils has been reported [5],
however, a greater amount of the zymogen was associated
into punctate clusters occupying the external surface of the
neutrophil membrane [9]. Tissue prokallikrein docks to the
plasma membrane via speci¢c cell-attachment sites [10], but
the structural identity of the putative zymogen acceptor mol-
ecule(s) is still unknown.
Similar clustered patterns of neutrophil-bound proteins
have been reported for HK and LK present in patchy spots
on the outer surface of the neutrophil membrane [11]. Both
kininogens are multifunctional plasma proteins with a com-
mon heavy chain and kinin moiety, respectively, but LK is
devoid of the speci¢c light chain sequences that reside in HK
[7]. Circulating neutrophils contain a considerable number of
kininogen-binding sites which may be compromised of one or
more candidate proteins. Recently, the leukocyte integrin
Mac-1 (CD11b/18) has been shown to serve as a major attach-
ment site for HK requiring a zinc-dependent interaction with
speci¢c domains of the heavy and light chain of HK, respec-
tively [12]. The functional signi¢cance of neutrophil-bound
kininogens is not yet fully delineated. Cell surface-anchored
kininogens might act as docking proteins for additional com-
ponents of the kallikrein-kinin system to trigger the kinin-
forming pathway which has already been established for
bimolecular complexes between HK and plasma prokallikrein
on the membrane of endothelial cells [13,14]. Therefore,
we have postulated a similar local assembly of tissue pro-
kallikrein and kininogens on the surface of human neutro-
phils that could contribute through the release of kinins to
the diapedesis of neutrophils during the in£ammatory re-
sponse.
Since speci¢c acceptor molecules are required for the
docking of tissue prokallikrein to neutrophils [10], it is of
particular interest to identify prokallikrein-binding proteins
and their potential relationship to the zymogen-binding sites
on neutrophil membranes. In this study, we have used re-
combinant tissue prokallikrein and puri¢ed kininogens to
investigate their possible interactions by direct binding and
ligand blotting assays. In addition, human plasma was
screened for proteins that speci¢cally bind to tissue prokalli-
krein.
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2. Materials and methods
2.1. Materials
Puri¢ed single-chain HK and LK were purchased from Calbiochem
(Bad Soden, Germany). Human serum albumin (HSA) and HK-de¢-
cient plasma (Fitzgerald trait) were obtained from Sigma (Deisenho-
fen, Germany). Normal plasma from healthy donors was collected by
two centrifugation steps (200Ug, 10 000Ug, 10 min each) from whole
blood immediately adjusted to 5.4 mM EDTA, 0.4 mM Pefabloc SC,
and 10 WM E-64 (Roche Diagnostics, Mannheim, Germany). Prepa-
ration of recombinant human tissue prokallikrein, which was pro-
duced in insect cells using the baculovirus expression system, and
conversion of the puri¢ed proenzyme to mature kallikrein followed
established protocols [6]. Puri¢ed prokallikrein, mature kallikrein, and
anti-TproK antibodies directed against the recombinant zymogen
were biotinylated with EZ-Link biotin hydrazide (Pierce, Rockford,
IL, USA) according to the manufacturer’s recommendations. The
degree of biotinylation was veri¢ed by an indirect ELISA using wells
coated with various dilutions of the labeled protein and biotin-BSA
(Sigma) as standards, respectively. Probing occurred with horseradish
peroxidase-conjugated streptavidin (Dianova, Hamburg, Germany)
and 2,2P-azino-bis(3-ethylbenzthiazoline)-sulfonate (ABTS, Roche Di-
agnostics).
2.2. Dot blot analysis
Samples were added to a grid pattern on a nitrocellulose membrane
(BA 83, Schleicher and Schu« ll, Dassel, Germany) and air dried for 2 h
at 4‡C. After blocking free sites overnight with 5% (w/v) BSA in
TBST-Ca (10 mM Tris^HCl, 150 mM NaCl, 2 mM CaCl2, 0.05%
Tween 20, pH 8), the dot blot was incubated with 0.5 Wg/ml (15
nM) biotinylated prokallikrein in blocking bu¡er in the presence or
absence of 50 WM Zn2 with or without competitor for 2 h at room
temperature. The membrane was washed three times in TBST-Ca and
the bound ligand detected with streptavidin-peroxidase for 1 h, fol-
lowed by the chemiluminescence system (ECL, Amersham Pharmacia,
Buckinghamshire, England).
2.3. Ligand blotting
Samples were treated at 42‡C for 30 min in bu¡er containing 0.5%
SDS, 100 mM Tris^HCl, pH 6.8, 25% glycerol, but no reducing
agents. After separation by SDS^PAGE, proteins were visualized
with Coomassie blue R-250 or transferred to BA 83 nitrocellulose
membranes by the semi-dry technique. Following incubation in
20 Wg/ml (0.6 WM) recombinant prokallikrein, bound ligand was
probed with biotinylated anti-TproK antibodies (800 ng/ml) and the
subsequent streptavidin-peroxidase/ECL reaction.
2.4. Quanti¢cation of kininogen-bound biotin-prokallikrein
A direct binding assay on HK-coated (250 ng/well), 96-well micro-
titer plates was performed at 37‡C in triplicate. Wells were blocked
with 2% BSA in PBS for 1 h and then incubated for 2 h with serial
dilutions of biotin-prokallikrein (starting concentration 67 Wg/ml = 1.9
WM) and biotin-kallikrein (starting concentration 64 Wg/ml = 1.9 WM),
respectively, both dissolved in PBS containing 1% BSA. After washing
with 0.05% Tween 20 in PBS, detection of bound proteins occurred
with streptavidin-peroxidase for 2 h, followed by the ABTS substrate
reaction for 30 min. The change in absorbance was monitored at
405 nm using a 340 ATTC ELISA reader (SLT Labinstruments,
Crailsheim, Germany). To convert the absorbance at each amount
of bound prokallikrein to pmoles zymogen bound, standard curves
were monitored by an indirect ELISA using microtiter plates coated
with serial dilutions of biotinylated prokallikrein. Non-speci¢c bind-
ing was determined by the level of binding seen with mature kalli-
krein. Equilibrium binding data were analyzed by linear regression
according to the method of Scatchard [15].
3. Results
In view of the fact that human tissue prokallikrein circu-
lates in plasma predominantly complexed with neutrophils [9],
initial experiments were performed to determine if cell surface
docking of prokallikrein can be mediated by plasma kinino-
gens. Using dot blot assays, puri¢ed HK and LK were com-
pared for their binding properties towards biotinylated pro-
kallikrein (Fig. 1A). Only HK and a positive method control
with prokallikrein-speci¢c antiserum displayed high a⁄nity
for nanomolar biotin-prokallikrein. No interaction was ob-
served with LK demonstrating that the prokallikrein-binding
site is comprised by the unique light chain of HK. Incubation
in the presence of a 50-fold molar excess of unlabeled kalli-
krein precursor signi¢cantly reduced the binding of biotinyl-
ated prokallikrein. This result indicated not only the reversi-
bility of the complex formation but also the speci¢city of
prokallikrein association to HK. The speci¢city of the test
system was further con¢rmed by an unrelated protein, human
serum albumin (HSA), which failed to show a binding signal.
In order to establish the optimal conditions for biotin-labeled
prokallikrein reacting with HK, studies were carried out to
determine the in£uence of zinc ions on the interaction between
HK and the kallikrein zymogen (Fig. 1B). The amount of
biotin-prokallikrein bound to HK in the presence of 50 WM
Zn2 was not signi¢cantly di¡erent from the level of binding
in the absence of Zn2, thus demonstrating that zinc ions had
no e¡ect on the complex formation of prokallikrein and HK.
The number and a⁄nity of tissue prokallikrein-binding sites
on HK were then determined at equilibrium as a function of
ligand concentration (Fig. 2A). When increasing amounts of
biotinylated prokallikrein and mature kallikrein, respectively,
were added to immobilized HK at 37‡C, kininogen bound the
kallikrein precursor most e⁄ciently in a dose-dependent man-
ner whereas the a⁄nity to the mature enzyme was signi¢cantly
lower. Speci¢c binding of prokallikrein reached saturation at
4 nM of the ligand, which represented approximately 0.4%
bound of the total kallikrein precursor present. To quantify
zymogen a⁄nity, binding of the kallikrein portion was sub-
tracted from total bound zymogen at each HK concentration
to obtain the contribution of the propart of prokallikrein
associated to kininogen. Analysis of the data by the graphical
method of Scatchard (Fig. 2B) indicated that biotin-prokal-
likrein bound with moderate a⁄nity to HK yielding an ap-
parent dissociation constant KD of 690 nM. The stoichiometry
Fig. 1. Dot blot analysis of tissue prokallikrein binding by various
plasma proteins. Immobilized proteins (2 Wg per spot) and 2 Wl anti-
prokallikrein antiserum (anti-TproK, 1:500 dilution) were probed
with biotinylated prokallikrein in the presence of a 50-fold molar
excess of unlabeled prokallikrein (competitor) (A), and in the pres-
ence of 50 WM zinc ions (B).
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of binding in the bimolecular complex was found to be 1:1 as
calculated from the total number of bound ligand (Bmax = 1.5
pmol/well) which was equivalent to the amount of immobi-
lized HK.
Since tissue prokallikrein appeared to bind selectively to
HK, a ligand blot was performed to assess prokallikrein-bind-
ing activity under physiological protein concentrations in hu-
man plasma (Fig. 3). SDS-denatured proteins were subjected
to Western blotting after electrophoretic separation and pro-
kallikrein-binding proteins were then visualized by the forma-
tion of a binding protein^prokallikrein^antibody complex on
the blot. In the complex mixture of plasma proteins, this assay
detected a speci¢c prominent band at 116 kDa in normal
human plasma, similar to the band obtained with commer-
cially puri¢ed HK. As a method control, the HK binding
could not be identi¢ed in kininogen-de¢cient plasma. Trace
reactivity of two other proteins in the 80^90 kDa range is seen
in normal plasma and kininogen-de¢cient plasma, respec-
tively. These additional bands might point to the existence
of further prokallikrein-binding proteins yet unidenti¢ed.
The intense band in the high-molecular-weight range (s 120
kDa) of both plasma samples re£ects an artifact of biotinyl-
ated anti-prokallikrein antibody as this reactivity was also
observed in the absence of the prokallikrein ligand (data not
shown).
4. Discussion
The study described above is the ¢rst to demonstrate spe-
ci¢c binding of human tissue prokallikrein to HK. This ¢nd-
ing is based on several experimental approaches. First, only
the high-molecular-weight form of puri¢ed native kininogens
recognized biotin-prokallikrein by dot blot and direct binding
assays, whereas we could not detect interactions between LK
and the biotinylated kallikrein precursor. Since the heavy
chains of both, LK and HK, are identical [7], this result
maps the domain important for prokallikrein interaction to
the light chain of HK. Structural features of the zymogen are
required for complex formation with HK because mature kal-
likrein displayed low a⁄nity for kininogen indistinguishable
from background binding. Second, ligand blotting with dena-
tured human plasma proteins and unmodi¢ed zymogen iden-
ti¢ed a major prokallikrein-binding protein corresponding to
HK. This biochemical evidence was supported by the obser-
vation that plasma from individuals de¢cient in HK was also
de¢cient in prokallikrein binding. Since native as well as de-
natured HK possessed strong a⁄nity for the kallikrein pre-
cursor, we conclude that tissue prokallikrein and HK interact
as native proteins.
The in vitro binding of recombinant tissue prokallikrein to
puri¢ed HK is characterized by one saturable site with an
apparent dissociation constant of 690 nM, which appears rel-
atively moderate compared to a 50-fold higher HK a⁄nity for
plasma prokallikrein [16]. However, previous studies to iden-
tify endothelial proteins which bind to HK demonstrated only
weak interactions between recombinant HK-binding protein
p33 and its ligand but high a⁄nity towards cell-bound p33
[17]. Conceivably, immobilization of HK on cell surfaces al-
ters its ability to interact with potential ligands by conforma-
tional changes and/or putative modulator proteins.
One implication of the ¢nding that HK is a prokallikrein-
Fig. 2. Direct binding of tissue prokallikrein to immobilized HK. The ability of HK to interact with increasing concentrations of biotinylated
prokallikrein and kallikrein, respectively, was determined by the streptavidin-peroxidase system (A). The best-¢t data of the ratio of bound/free
versus bound prokallikrein are presented in a Scatchard plot (B).
Fig. 3. Detection of a prokallikrein-binding protein in human plas-
ma. Puri¢ed HK (lane 1, 2 Wg), plasma (lane 2, 50 Wg) and HK-de-
¢cient plasma (lane 3, 50 Wg) were resolved by 10% SDS^PAGE
under non-reducing conditions. Proteins were visualized by Coomas-
sie staining (left panel) and ligand blotting in the presence of re-
combinant human tissue prokallikrein (right panel). The arrow indi-
cates the relative position of HK. Molecular masses of marker
proteins are given on the left.
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binding protein relates to previous reports on neutrophil
docking sites for the zymogen of tissue kallikrein [9,10].
Although we have no direct evidence demonstrating HK as
a neutrophil-bound prokallikrein receptor, HK has been
shown on the surface of many cardiovascular cells such as
platelets, endothelial cells, and neutrophils [7], and our results
are not incompatible with the hypothesis that HK docked on
cell membranes may function as an acquired receptor for tis-
sue prokallikrein. Thus, although the participation of other
cell surface proteins is not excluded, the current study impli-
cates the high-molecular-weight form of kininogens as a pro-
tein which may contribute prominently to the binding func-
tion of neutrophils towards the tissue kallikrein precursor.
De¢nite evidence to clarify this intriguing suggestion must
await additional experiments to identify the exact nature of
the neutrophil-binding site for tissue prokallikrein.
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